NICE recommends Lynparza (olaparib) to treat ovarian cancer- AstraZeneca

The UK's National Institute for Health and Care Excellence (NICE) now recommends Lynparza (olaparib) from AstraZeneca to treat patients with BRCA mutation positive ovarian cancer. This is a reversal of an earlier decision after AstraZeneca supplied further evidence. The recommendation applies to maintenance treatment for patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancers who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based chemotherapy. Patients will need to have treatment with at least three courses of platinum-based chemotherapy. AstraZeneca has offered to meet the cost for patients who remain on the drug after 15 months.